Omega Research Orlando, LLC

Orlando, Florida 32808

3 studies enrolling now · 14 studies all time

What they study most

COVID-19, Chronic Kidney Diseases, Covid19, Dermatomyositis, End Stage Kidney Disease, End Stage Renal Disease (ESRD), Healthy, Hepatic Insufficiency, Kidney Disease, Kidney Failure, Chronic, Liver Diseases, Liver Fibrosis

Studies at this site

• LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis — Recruiting now
• LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis — Recruiting now
• A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function — Recruiting now
• A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems — Completed
• A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis — Completed
• A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment — Completed
• ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 — Completed
• Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD) — Stopped early
• EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19 — Completed
• A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3) — Completed
• A Study to Test How BI 690517 is Taken up in the Body of People With and Without Liver Problems — Completed
• Study to Compare the Pharmacokinetics and Pharmacodynamics of ASA Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Adult Subjects With Obstructive or Restrictive Pulmonary Function — Stopped early
• Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR). — Stopped early
• Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients. — Stopped early